A5005547740- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Eosinophilic Disorders and Syndromes
- Integrated Circuits and Semiconductor Failure Analysis
- Neuroendocrine Tumor Research Advances
- CNS Lymphoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Parvovirus B19 Infection Studies
- Hematological disorders and diagnostics
- Circular RNAs in diseases
- Adolescent and Pediatric Healthcare
- MRI in cancer diagnosis
- Kruppel-like factors research
- Neutropenia and Cancer Infections
- Chemokine receptors and signaling
- MicroRNA in disease regulation
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Herpesvirus Infections and Treatments
- Immune cells in cancer
Second Hospital of Anhui Medical University
2016-2025
Anhui Medical University
2013-2025
Abstract Background Elevated red blood cell distribution width (RDW) and decreased platelet count (PLT) can be clinically relevant to the prognosis in cancer patients. However, their prognostic values patients with diffuse large B-cell lymphoma (DLBCL) need further explored. Methods Healthy donors ( n = 130) DLBCL 349) were included evaluated retrospectively this study. The influence of clinical pathological factors including RDW PLT on overall survival (OS) progression-free (PFS) studied by...
Long non-coding RNA HOTAIR has been reported to play a key role in regulating various biological processes cancers. However, the roles and mechanisms of acute myeloid leukaemia (AML) are still unclear need be investigated. In this study, we induced differentiation four AML cell lines by all-trans retinoic acid (ATRA) found was significantly upregulated process. Chromatin immunoprecipitation (ChIP) assays indicated that C/EBPβ during ATRA HL-60 cells. By gain- loss-of-function analysis, then...
Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1-S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to in vitro vivo. Our findings revealed genes were aberrantly...
The Philadelphia (Ph; BCR-ABL) chromosome originates from a translocation event between chromosomes 9 and 22, results in the BCR-ABL fusion gene. In chronic myelogenous leukemia (CML), gene is mainly coded for by major breakpoint cluster region (M-bcr, e13a2 e14a2). However, some patients, genes are encoded minor (m)-bcr, e1a2, micro (µ)-bcr region, e19a2. These transcripts revealed different clinical course. present study described CML patient whose cytogenetics FISH analyses of bone marrow...
Our aim was to explore the relationship between JAK2V617F mutation allele burden and hematological parameters especially in coagulation function Chinese population.This study included 133 Ph-negative myeloproliferative neoplasms (MPNs) patients 2013 2016. All clinical experimental data of were collected at time diagnosis without any prior treatment, including blood parameters, function, splenomegaly, vascular events chromosome karyotype. PCR qPCR used detect burden.In polycythemia vera...
For patients exhibiting a suboptimal response to the first chimeric antigen receptor (CAR) T-cell therapy (CART1) or relapse after remission, secondary CAR (CART2) for same target may be an option. We retrospectively analyzed with acute B-cell lymphoblastic leukemia (B-ALL) receiving CD19 CART1 at our center (n = 84) report clinical outcomes of CART2 and identify factors that influence outcomes. Twenty-six received post-CART1. The incidence cytokine release syndrome (CRS) was 65.4% (17/26),...
Relapsed diffuse large B-cell lymphoma (DLBCL) is a disease with poor prognosis. Recent clinical trials results showed chimeric antigen receptor (CAR) T cell therapy has promising role in treating relapsed DLBCL. Unfortunately, patients extranodal lesions respond poorly to CAR-T cells administered intravenously. Herein, we evaluated the efficacy and safety of new treatment strategy cells, combining intravenous infusion local injection DLBCL patient lesions. The achieved durable remission...
<div>Abstract<p>Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1–S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to <i>in vitro</i>...
<div>Abstract<p>Differentiation therapy based on ATRA almost cured acute promyelocytic leukemia (APL). However, it is disappointing that not effective against other myeloid (AML) subtypes. Developing new and anti-AML therapies promote differentiation necessary. The CDK4/6-cyclin D pathway a key initiator of the G1–S phase transition, which determines cell fate. Herein, we investigated whether CDK4/6 inhibitor palbociclib would synergize with to <i>in vitro</i>...
<p>Figure S3. Knockdown CDK4 and CDK6 via siRNA in HL-60 molm13 cells (A). The effect of palbociclib ATRA combination on cell cycle(B), proliferation (C), apoptosis (D). * Represent when it compares with the control group, P<0.05. # P<0.05.</p>
<p>Figure S2. The comparison of the expression CDK4/6-cyclin D pathway genes based on age (A) and risk stratification (B). Kaplan-Meier curve for CDK6 (C). calibration nomogram 1-year 2-year overall survival (D).</p>
<p>Figure S4. The effect of Palbociclib and ATRA combination on leukemia burden in vivo (A). Volcano plots differentially expressed genes HL-60 cells (B) molm13 (C) from the control palbociclib groups.</p>
<p>Table S1</p>
<p>Supplementary Figure Legends</p>
<p>Figure S3. Knockdown CDK4 and CDK6 via siRNA in HL-60 molm13 cells (A). The effect of palbociclib ATRA combination on cell cycle(B), proliferation (C), apoptosis (D). * Represent when it compares with the control group, P<0.05. # P<0.05.</p>
<p>Figure S1. The mutation frequency of CDK4/6-cyclin D pathway genes, CDKN1A and CDKN2A in 531 AML patients (A). expression was compared between healthy donors the BeatAML database. * Represent P<0.05.</p>
<p>Figure S1. The mutation frequency of CDK4/6-cyclin D pathway genes, CDKN1A and CDKN2A in 531 AML patients (A). expression was compared between healthy donors the BeatAML database. * Represent P<0.05.</p>
<p>Table S1</p>
<p>Supplementary Figure Legends</p>
<p>Figure S4. The effect of Palbociclib and ATRA combination on leukemia burden in vivo (A). Volcano plots differentially expressed genes HL-60 cells (B) molm13 (C) from the control palbociclib groups.</p>
<p>Figure S2. The comparison of the expression CDK4/6-cyclin D pathway genes based on age (A) and risk stratification (B). Kaplan-Meier curve for CDK6 (C). calibration nomogram 1-year 2-year overall survival (D).</p>